A faster path to the most effective treatment with better outcomes
We develop holistic profiles based on a patient’s personal health data, demographics, social determinants of health, and other relevant factors pertinent to the ultimate outcomes.
Multidimensional datasets are acquired from fluorescent emissions using an array of nanoscale sensing elements that detect health abnormalities and signals of treatment effectiveness in small patient samples.
Get patients the most effective treatment faster by providing feedback to select and optimize treatment faster.
Researchers and drug developers can now understand new biology with biomarkers that react dynamically, in real time, directly from patients.
Clinicians can accelerate validation of precision medical treatments in real patient situations.
Patients ultimately get the most effective treatment as soon as possible.
Nine Diagnostics CEO and Co-Founder Freddy T. Nguyen, MD, PhD, appeared on Episode 40 of the Pitt HexAI Podcast to discuss AI-enabled cancer diagnostics and the entrepreneurship pathway behind Nine…
Nine Diagnostics CEO and Co-Founder Freddy T. Nguyen, MD, PhD, joined KAMI Think Tank’s From Models to Medicine podcast for Episode 8, “The Equity Gap in Diagnostic AI,” a candid…
Nine Diagnostics is participating in the Spring 2026 DRIVE Accelerator Biomarkers and Diagnostics track, a national program run by SCbio in partnership with MassBio supporting early-stage companies advancing next-generation diagnostic…
Nine Diagnostics participated in the BioTools Innovator East Coast Road Tour pitch event, a competitive selection process run by BioTools Innovator, the first accelerator focused exclusively on life science tools…
Nine Diagnostics co-founders Daniel A. Heller, PhD, and Mijin Kim, PhD, co-authored a perspective in Nano Letters reviewing the current landscape and outlook for the industrial integration of carbon nanotubes…
Nine Diagnostics was selected to present at the FNIH Biomarkers Consortium 20th Anniversary Symposium, a leading forum convening senior leaders across academia, industry, and government to advance biomarker science. The…
Nine Diagnostics co-founders Daniel Heller and Mijin Kim are contributing to the ARPA-H LIGHT program as part of the Weill Cornell Medicine-led LANTERN team, one of 11 groups funded through…
Nine Diagnostics and Orbits Oncology have entered into an exploratory partnership to jointly develop a next-generation precision oncology diagnostics platform. The collaboration pairs Nine Diagnostics' nanosensor-based molecular fingerprinting, which captures…
Nine Diagnostics co-founders Daniel A. Heller, PhD, and Mijin Kim, PhD, co-authored a cover article in Nature Nanotechnology (February 2026) demonstrating 98% accuracy in brain tumor detection and 71% accuracy…
Nine Diagnostics graduated from the American Cancer Society BrightEdge Entrepreneurs Program, culminating in a Demo Day pitch presentation of the Nine Diagnostics nanosensor-enabled, machine learning-driven diagnostic platform. The 10-month program,…
Nine Diagnostics co-founder Daniel A. Heller, PhD, was featured on KVIA-TV ABC-7 News El Paso in October 2025 for his work developing a nanosensor-based liquid biopsy for early ovarian cancer…
Nine Diagnostics was selected to present at the second annual Boston Biotech Investor Day, an invitation-only Seaport event co-hosted by LabCentral, BioLabs, The Engine, and the Termeer Institute, bringing together…
Nine Diagnostics co-founder Dr. Daniel Heller was featured in Women's Health Magazine discussing why ovarian cancer remains so difficult to detect early and how AI-enabled nanosensor technology is changing that…
Freddy T. Nguyen, MD, PhD, CEO and Co-Founder of Nine Diagnostics, co-authored a paper in Applied Spectroscopy Practica presenting a framework for translating measurement science into healthcare products, drawn from…
Nine Diagnostics co-founder and CEO Dr. Freddy T. Nguyen has been named a 2025 Scholar in Diagnostic Excellence by the National Academy of Medicine, recognizing leaders advancing diagnostic quality, safety,…
Nine Diagnostics CEO Dr. Freddy Nguyen delivered an MIT Startup Exchange Lightning Talk at the 2025 MIT Health Science Forum, hosted by the MIT Industrial Liaison Program, an event convening…
Nine Diagnostics co-founders Daniel A. Heller, PhD, and Mijin Kim, PhD, co-edited a two-volume reference work on carbon nanomaterials in biomedicine, published by World Scientific in 2025 as part of…
Nine Diagnostics was selected to join the American Cancer Society's BrightEdge Entrepreneurs Program, a competitive initiative supporting oncology startups with high-impact potential. The program provides access to top-tier mentorship, investment…
Nine Diagnostics co-founder Dr. Daniel Heller was featured in BBC News as part of its "AI Breakthroughs" series, discussing how AI and nanotechnology could transform detection of ovarian and other…
Nine Diagnostics joined a U.S.-Dutch consortium to co-produce a white paper on advancing diagnostic tools and treatments for gynecological cancers, serving as the molecular diagnostics partner with its AI-enabled multiomics…
Nine Diagnostics was accepted into Merck Digital Sciences Studio Cohort 3, a 10-month digital accelerator providing direct investment, strategic mentorship, and industry connections to early-stage biomedical startups advancing AI and…
Nine Diagnostics was selected for the inaugural cohort of the CancerHackerLab Accelerator, a cancer-focused innovation program connecting early-stage oncology companies with clinical mentors, biopharma advisors, patient advocates, and a peer…
Nine Diagnostics was selected as one of two recipients of the 2024 Novo Nordisk Golden Ticket, a competitive award run jointly by Novo Nordisk’s Bio Innovation Hub and LabCentral recognizing…
Nine Diagnostics was selected to participate in The Engine's Blueprint program, a competitive early-stage cohort for tough tech companies co-founded by MIT, with participation beginning September 13, 2024. The program…
Nine Diagnostics was selected to participate in the NSF I-Corps Program at MIT, a structured customer discovery program administered through the New England Regional Innovation Node at MIT, with participation…
Nine Diagnostics was incorporated on March 8, 2024, bringing together Freddy T. Nguyen, MD, PhD, Daniel A. Heller, PhD, and Mijin Kim, PhD to build an AI-enabled multi-omic nanosensor platform…
Daniel A. Heller, PhD, lead researcher in the Cancer Nanomedicine Lab at Memorial Sloan Kettering Cancer Center, was featured on NBC New York (WNBC-TV 4) in February 2024 for his…
Mijin Kim, PhD, a postdoctoral researcher in the Cancer Nanomedicine Lab at Memorial Sloan Kettering Cancer Center, was named a 2023 STAT Wunderkind, an annual honor recognizing early-career researchers whose…
Mijin Kim, PhD, a postdoctoral researcher in the Cancer Nanomedicine Lab at Memorial Sloan Kettering Cancer Center, was named to MIT Technology Review's 2022 Innovators Under 35 list in the…
Mijin Kim, PhD, and Daniel A. Heller, PhD, at Memorial Sloan Kettering Cancer Center published a landmark study in Nature Biomedical Engineering (March 2022) demonstrating that quantum-defect-modified carbon nanotube nanosensor…
Daniel A. Heller, PhD, and colleagues at Memorial Sloan Kettering Cancer Center published a study in Science Advances (November 2021) introducing a perception-based nanosensor platform for detecting cancer biomarkers, demonstrating…
